Trial · NCT04435366
Results by group43
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 43
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 | Avacincaptad Pegol | 0.336 | Standard Error 0.032 | millimeters (mm)/year | |
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by Autofluorescence (FAF) at 3 Time Points: Baseline, Month 6, and Month 12 | Sham | 0.392 | Standard Error 0.033 | millimeters (mm)/year | |
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 | Avacincaptad Pegol | 2.23 | Standard Error 0.124 | mm^2/year | |
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 | Avacincaptad Pegol and Sham | 2.10 | Standard Error 0.126 | mm^2/year | |
| The Mean Rate of Growth (Slope) Estimated Based on GA Area Measured by FAF at 5 Timepoints: Baseline, Month 6, Month 12, Month 18, and Month 24 | Sham | 2.59 | Standard Error 0.085 | mm^2/year | |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months | Avacincaptad Pegol | -7.31 | Standard Error 1.07 | score on a scale | |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) Using Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at 24 Months | Sham | -6.48 | Standard Error 1.05 | score on a scale | |
| Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months | Avacincaptad Pegol | -10.58 | Standard Error 1.20 | score on a scale | |
| Change From Baseline in Low Luminance (LL) BCVA Using ETDRS Letters at 24 Months | Sham | -9.1 | Standard Error 1.18 | score on a scale | |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | Avacincaptad Pegol | Change at 6 months | -1.2 | Standard Deviation 10.56 | score on a scale |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | Sham | Change at 6 months | -1.6 | Standard Deviation 9.98 | score on a scale |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | Avacincaptad Pegol | Change at 12 months | -3.4 | Standard Deviation 11.05 | score on a scale |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | Sham | Change at 12 months | -3.6 | Standard Deviation 11.01 | score on a scale |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | Avacincaptad Pegol | Change at 18 months | -5.4 | Standard Deviation 12.80 | score on a scale |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 6, 12 and 18 Months | Sham | Change at 18 months | -4.7 | Standard Deviation 11.53 | score on a scale |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months | Avacincaptad Pegol | -7.735 | Standard Error 0.950 | score on a scale | |
| Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Scores at 24 Months | Sham | -7.023 | Standard Error 0.931 | score on a scale | |
| Number of Participants With Categorical One-level Loss in VFQ-25 Subscale | Avacincaptad Pegol | Color Vision | 45 | participants | |
| Number of Participants With Categorical One-level Loss in VFQ-25 Subscale | Sham | Color Vision | 35 | participants | |
| Number of Participants With Categorical One-level Loss in VFQ-25 Subscale | Avacincaptad Pegol | Distance Vision | 56 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04435366/results